Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-25959 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ADAM9 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 2 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Long NP, Jung KH, Anh NH, Yan HH, Nghi TD, Park S, Yoon SJ, Min JE, Kim HM, Lim JH, Kim JM, Lim J, Lee S, Hong SS, Kwon SW
Cancers 2019 Jan 29;11(2)
Cancers 2019 Jan 29;11(2)
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
Li W, Wang D, Sun X, Zhang Y, Wang L, Suo J
International journal of molecular medicine 2019 Feb;43(2):914-926
International journal of molecular medicine 2019 Feb;43(2):914-926
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Oria VO, Lopatta P, Schmitz T, Preca BT, Nyström A, Conrad C, Bartsch JW, Kulemann B, Hoeppner J, Maurer J, Bronsert P, Schilling O
Molecular oncology 2019 Feb;13(2):456-479
Molecular oncology 2019 Feb;13(2):456-479
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis using an ADAM9 polyclonal antibody (Product # PA5-25959) in MDA-MB231 cell lysates (35 µg per lane).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of formalin-fixed, paraffin-embedded human lung carcinoma tissue using an ADAM9 polyclonal antibody (Product # PA5-25959), followed by HRP-conjugated secondary antibody and DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of MCF-7 cells using an ADAM9 polyclonal antibody (Product # PA5-25959) (bottom) compared to a negative control cell (top) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Immunohistochemical analysis showing the expression of ADAM8, ADAM9, ADAM10, ADAM12 and ADAM17 in adjacent non-cancerous gastric tissues, gastric cancer tissues, positive metastatic lymph node tissues, and negative metastatic lymph node tissues. Scale bars, 50 u M. ADAM, disintegrin and metalloproteinase domain-containing protein.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Immunohistochemical analysis for determination of LAMC2 , ADAM9 , and ANXA2 ( Annexin A2 ) gene expression. ( a ) Scoring system for the three proteins in pancreatic tissues. ( b ) IHC scores of LAMC2 , ADAM9 , and ANXA2 in pancreatic tumors and normal controls ( n = 86). ***: p < 0.001; ****: p < 0.0001. ( c ) Pairwise correlation of LAMC2 , ADAM9 , and ANXA2 expression. ( d ) Pairwise correlation of LAMC2 , ADAM9 , and ANXA9 at gene expression level (log 2 of transcripts per million) in TGCA PC, TCGA normal pancreas, and Genotype-Tissue Expression Project (GTEx) derived normal pancreas.
